Envision (EVHC) ALERT: Johnson Fistel Investigates Proposed Sale of Envision Healthcare Corporation; Is $46.00 a Fair Price for Shareholders?
SAN DIEGO- PRNewswire —June 11, 2018
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Envision Healthcare Corporation (NYSE: EVHC) (“Envision”) breached their fiduciary duties in connection with the proposed sale of the Company to KKR.
June 11, 2018, Envision announced that it had signed a definitive merger agreement with KKR. Under the terms of the agreement, KKR will acquire all of the outstanding shares of Envision’s common stock for $46.00 per share in cash.
The investigation concerns whether the Envision board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Envision shares of common stock.
Nationally recognized Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given one Wall Street analyst has a $51.00 price target on the stock. The 52-week high for Envision was $64.00.
If you are a shareholder of Envision and believe the proposed buyout price is too low or you’re interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (email@example.com) at 619-814-4471. If emailing, please include a phone number.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.